Promise Proteomics announces CE-IVD marking of its mAbXmise kits for therapeutic drug monitoring by mass spectrometry
October 22, Lyon – After 10 years of research and development, Promise Proteomics is bringing to market the first commercial solution allowing quantification of these innovative therapies by mass spectrometry, and has been granted CE-IVD marking for the first two products in the range.
“mAbXmise kits are a unique patented solution combining labelled monoclonal antibodies, reagents and laboratory supplies to quantify therapeutic monoclonal antibodies. This multiplexed method outperforms other analytical methods, thus providing scientific, clinical and economic perspectives that fully meet the constraints of routine therapeutic drug monitoring” indicates Dorothée LEBERT, CSO of Promise Proteomics. To know more
